CGTN: China Outlines Four-point Proposal for the Future of APEC
21.11.2020 19:05:00 EET | Business Wire | Press release
With the world and the Asia-Pacific region undergoing profound changes, China has called for joint efforts to build an Asia-Pacific community with a shared future featuring openness, inclusiveness, innovation-driven growth, greater connectivity, and mutually beneficial cooperation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201121005045/en/
Read the original article here.
China highly values the role of the Asia-Pacific Economic Cooperation (APEC) and will continue to support the development of the organization, President Xi Jinping said on Friday when addressing the APEC Economic Leaders' Meeting in Beijing via video link.
Established in 1989, APEC has become an important platform to facilitate economic cooperation among 21 economies in the Asia-Pacific region.
However, the region is currently facing challenges such as backlashes against economic globalization, rising unilateralism, and protectionism, as well as the fallout from the COVID-19 pandemic.
"For the first time in decades, the Asia-Pacific as a whole registered negative economic growth," Xi said. "Protecting people's health and reviving the economy are two formidable tasks we have to take on."
The Chinese president outlined a four-point proposal for the future of Asia-Pacific cooperation.
Read more:
Foreign leaders urge APEC members to advocate multilateral trade
Open and inclusive
"First, we need to stay open and inclusive," Xi said. "It is important that the Asia-Pacific should remain the bellwether in safeguarding peace and stability, upholding multilateralism, and fostering an open world economy."
He called for further efforts to promote regional economic integration for the early realization of a Free Trade Area of the Asia-Pacific (FTAAP).
The FTAAP proposal was initiated in 2004 and written into the declaration of the APEC meeting in 2006. During the 2014 APEC meeting in Beijing, the initiative made a breakthrough, with APEC members unanimously adopting the FTAAP Beijing Roadmap to achieve the goal.
The recent signing of the Regional Comprehensive Economic Partnership (RCEP) free trade agreement was viewed as a significant step toward the establishment of the FTAAP.
The pact was signed on Sunday among its 15 participating countries, including the 10 member countries of the Association of Southeast Asian Nations and China, Japan, South Korea, Australia, and New Zealand.
"China welcomes the signing of the RCEP and will favorably consider joining the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP)," Xi said.
Effective since December 30, 2018, the CPTPP is a trade pact among 11 countries, including Japan, Canada, Australia, Singapore, Chile, and Mexico, whose aggregate gross domestic product accounts for 13 percent of the world economy.
Efforts should be made to "promote free and open trade and investment, and make economic globalization more open, inclusive, balanced and beneficial to all," he said.
Innovation-driven growth
"Second, we need to pursue innovation-driven growth," Xi said, calling for improving the digital infrastructure and bridging the digital divide in the region.
Asia-Pacific economies should "foster an open, fair, equitable and non-discriminatory environment for businesses," he stressed.
Digital technologies should play a bigger role in facilitating experience sharing on epidemic control, boosting economic recovery, and eradicating poverty in the region, he suggested.
The emphasis on innovation is in line with China's own priorities on development. The country vows to uphold the central role of innovation in its modernization drive and take self-reliance in science and technology as a strategic underpinning for national development, according to a newly unveiled blueprint for its development in the next 15 years.
"Third, we need to enhance connectivity," Xi added, calling connectivity a "vital basis of regional economic integration."
He pledged active efforts to set up "green lanes" with other parties to help make customs clearance more efficient during the pandemic and stabilize industrial and supply chains in the region and beyond.
The Chinese president also expressed the hope to work with other parties to build a high-quality Belt and Road.
Not a 'zero-sum political game'
"Fourth, we need to promote mutually beneficial cooperation," he said, stressing that economies in the region are highly complementary to each other.
"Our economic cooperation has never been a zero-sum political game in which one's loss is another's gain," he said. "Rather, our cooperation has provided us with a development platform to ensure what we each do can be mutually reinforcing and beneficial to all."
Xi called for advancing research of the development of COVID-19 vaccines and make them a global public good affordable in developing countries.
At the virtual meeting hosted by Malaysia, APEC launched a Post-2020 vision – the APEC Putrajaya Vision 2040, which is the bloc's new long-term blueprint for future cooperation. It laid out three economic drivers: "trade and investment," "innovation and digitalization," and "strong, balanced, secure, sustainable and inclusive growth."
The 2020 Kuala Lumpur Declaration was also issued at the meeting, calling for solidarity to defeat the pandemic and revive the economy across the region.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201121005045/en/
Contact information
Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
